BDX · 8-K · 20260806PR053790
Revenue Performance and Mix
BECTON DICKINSON & CO · 2026-08-06 · Importance 31 · Surprise 32 · From source text
Third-quarter fiscal 2026 revenue increased 5.4% as reported and 4.4% on a foreign-currency-neutral basis to $4.983 billion from $4.726 billion. United States revenue rose 6.9% to $3.081 billion, while international revenue increased 3.2% to $1.902 billion, or 0.6% on an FX-neutral basis. Medical Essentials revenue increased 4.5% to $1.675 billion, Connected Care rose 4.9% to $1.224 billion, BioPharma Systems increased 6.6% to $670 million, and Interventional rose 6.4% to $1.414 billion. Within the segments, Advanced Patient Monitoring revenue grew 10.9% to $309 million and Surgery revenue increased 7.0% to $422 million, while international BioPharma Systems revenue declined 2.8% to $467 million as reported and 6.2% on an FX-neutral basis.
Key facts
- Nine months ended June 30, 2026 net income: $449 million versus $1,185 million prior year (down 62.1%). source
- Net income (GAAP) for the three months ended June 30, 2026: $377 million versus $574 million prior year (down 34.3%). source
- Third quarter fiscal 2026 revenue: $5.0 billion, increased 5.4% as reported and 4.4% on a foreign currency neutral basis. source
- Total revenues for the three months ended June 30, 2026: $4,983 million versus $4,726 million in the prior year period (5.4% reported change, 4.4% FXN). source
- Supplemental revenue detail: U.S. Medical Essentials Medication Delivery Solutions revenue for the three months ended June 30, 2026: $720 million (5.9% change vs prior year). source
- Net income from continuing operations for the three months ended June 30, 2026: $451 million (essentially flat versus $451 million prior year: 0.1% change). source
- Supplemental revenue detail: International BioPharma Systems revenue for the three months ended June 30, 2026: $467 million, 3.6% reported change and 1.6% FXN. source
- Medical Essentials segment revenue for the three months ended June 30, 2026: $1,675 million, up 4.5% reported and 3.2% FXN. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | -14.8% | Nine months ended June 30, 2026 net income: $449 million versus $1,185 million prior year (down 62.1%). |
| revenue | positive | realized | +5.2% | Total revenues for the three months ended June 30, 2026: $4,983 million versus $4,726 million in the prior year period (5.4% reported… |
| revenue | positive | realized | +0.8% | Supplemental revenue detail: U.S. Medical Essentials Medication Delivery Solutions revenue for the three months ended June 30, 2026: $720… |